Publications
Featured Publications
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)
Journal for ImmunoTherapy in Cancer (JITC)
November 2023
Preclinical efficacy and immune activity of half-life extended IL-18 fusion proteins resistant to IL-18BP suppression
Society for Immunotherapy of Cancer (SITC)
November 2024
Tumor microenvironment pharmacodynamic effect of nemvaleukin less frequent intravenous dosing in multiple solid tumors: results from the phase 1/2 ARTISTRY-3 study
Society for Immunotherapy of Cancer (SITC)
November 2024
All Publications
Nemvaleukin Alfa Combination Therapy for Gastrointestinal (GI) Cancers: Preclinical Evidence and Clinical Data From the ARTISTRY-1 Trial
Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO GI)
Use of Quantitative System Pharmacology (QSP) Modeling to Optimize Dosing Frequency and Interval for Nemvaleukin Alfa, an Investigational Cancer Immunotherapy
Quantitative Systems Pharmacology Conference
April 2022
ARTISTRY-7: a Phase 3, Multicenter Study of Nemvaleukin Alfa, a Novel Engineered Cytokine, in Combination With Pembrolizumab Versus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Society of Gynecologic Oncology Annual Meeting on Women's Cancer
March 2022
Clinical outcomes of ovarian cancer patients treated with the novel engineered cytokine nemvaleukin alfa in combination with the PD-1 inhibitor pembrolizumab: recent data from ARTISTRY-1
Society of Gynecologic Oncology Annual Meeting on Women's Cancer
March 2022
Nemvaleukin Alfa in Patients With Advanced Renal Cell Carcinoma: ARTISTRY-1
American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
February 2022
Nemvaleukin Alfa Monotherapy in Patients With Advanced Melanoma: ARTISTRY-1
Melanoma Bridge
December 2021
Nemvaleukin Alfa, a Novel Engineered IL-2 Cytokine, in Combination With the Anti-PD-1 Antibody Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (ION-01 Study)
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2021
ARTISTRY-6: Nemvaleukin Alfa Monotherapy in Patients With Advanced Mucosal and Cutaneous Melanoma
Society for Melanoma Research Congress
October 2021
Clinical Development of Nemvaleukin Alfa (ALKS 4230) for Advanced Solid Tumors With High Unmet Need: From Design to Bench to Bedside
Cytokines in Cancer Immunotherapy Workshop
October 2021
Antitumor Efficacy and Immune Profiling of the Mouse Ortholog of Nemvaleukin Alfa, a Novel Engineered IL-2 Fusion Protein, in an Orthotopic Mouse Model of Small Cell Lung Cancer Alone or in Combination with Standard Chemotherapy
European Society for Medical Oncology (ESMO) Congress
September 2021
ARTISTRY-6: Nemvaleukin Alfa Monotherapy in Patients With Advanced Mucosal and Cutaneous Melanoma
European Society for Medical Oncology (ESMO) Congress
September 2021
Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys
The Journal of Pharmacology and Experimental Therapeutics
August 2021